FDA Accepts Biologics License Application for PaxVax's Single-Dose Oral Cholera Vaccine Vaxchora

PaxVax Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the Biologics License Application (BLA) for its affiliate PaxVax Bermuda Ltd.'s single-dose oral cholera vaccine Vaxchora™. PaxVax also announced today that the FDA has granted Vaxchora priority review status. If licensed, Vaxchora would be the only vaccine in the U.S. against cholera and PaxVax's second FDA-licensed vaccine after Vivotif® (typhoid fever vaccine). "Travelers residing in the U.S. currently have very few options to protect themselves against cholera when going abroad, and we are pleased with the progress we are making